NRXS Q1 2026 Earnings Call Summary

NeurAxis Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $1.6 million, an 80% increase from $896,000 in Q1 2025, marking the strongest quarterly revenue in the company's history.
Average Selling Price (ASP): Increased by 33% to $1,017 per device, up from $766 in Q1 2025.
Gross Margin: Expanded to 86.4% from 84.4% year-over-year, attributed to a shift towards higher-margin full reimbursement payers.
Operating Expenses: Totaled $3.1 million, a slight increase of 3% compared to Q1 2025.
Operating Loss: Reduced to $1.7 million, down 24% from $2.3 million in Q1 2025.
Net Loss: Decreased to $1.8 million, a 23% reduction compared to the previous year.
Cash Position: $7.1 million as of March 31, 2026, with a projected burn rate of approximately $1 million per quarter moving forward.

2. Strategic Updates and Business Highlights

CPT Code Adoption: The Category 1 CPT code for PENFS became effective January 1, 2026, facilitating better billing and reimbursement processes.
Insurance Coverage: Over 100 million covered lives, with significant progress in payer discussions, particularly with large national payers.
Key Performance Indicators (KPIs):
- 32% approval rate for prior authorizations, up from 12% in 2025.
- 66 accounts ordered IB-Stim in Q1 2026, an 18% increase from the previous year.
- Revenue per ordering account increased by 53% to $24,000.
Commercial Strategy: Focus on children's hospitals where coverage and demand are strongest, with plans to enhance sales and marketing efforts and hire additional personnel to support growth.

3. Forward Guidance and Outlook

Growth Expectations: Management is optimistic about a multi-year growth cycle, driven by improved payer coverage and execution in existing markets.
Cash Flow Breakeven: Anticipated to be achieved with approximately $15 million in annual revenue, based on current growth trajectories.
Sales and Marketing Expenses: Expected to increase as the company hires additional staff to drive top-line growth.

4. Bad News, Challenges, or Points of Concern

Payer Coverage: While progress is being made, comprehensive payer coverage remains a challenge, with the need for strong medical policy coverage across a significant portion of the payer mix.
Market Execution: The company recognizes that execution is complex and requires ongoing efforts to convert access into utilization.
Regulatory and Competitive Risks: The need for a large randomized controlled trial for adult IB-Stim coverage could delay broader market adoption.

5. Notable Q&A Insights

Breadth vs. Depth: Management emphasized a focus on deepening relationships with top accounts while also expanding the number of accounts. The goal is to ensure that accounts have sufficient payer coverage before scaling.
Projected Burn Rate: Expected to trend lower, with a target of $1 million or less per quarter for the remainder of the year.
Prior Authorization Goals: The target is to achieve an 80% approval rate for prior authorizations, with ongoing efforts to engage key payers and decision-makers.

Overall, NeurAxis reported strong financial growth in Q1 2026, driven by the adoption of the CPT code and improved payer coverage. However, challenges remain in achieving comprehensive insurance coverage and executing effectively in the market. The company is strategically focused on deepening existing relationships while expanding its account base.

NRXS — NeurAxis, Inc.